FI114550B - Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi - Google Patents

Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi Download PDF

Info

Publication number
FI114550B
FI114550B FI934145A FI934145A FI114550B FI 114550 B FI114550 B FI 114550B FI 934145 A FI934145 A FI 934145A FI 934145 A FI934145 A FI 934145A FI 114550 B FI114550 B FI 114550B
Authority
FI
Finland
Prior art keywords
ser
human
antibody
amino acid
thr
Prior art date
Application number
FI934145A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI934145A0 (fi
FI934145A (fi
Inventor
Jose Saldanha
Norman Hardman
Frank Kolbinger
Original Assignee
Novartis Ag
Tanox Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220228A external-priority patent/GB9220228D0/en
Application filed by Novartis Ag, Tanox Biosystems Inc filed Critical Novartis Ag
Publication of FI934145A0 publication Critical patent/FI934145A0/fi
Publication of FI934145A publication Critical patent/FI934145A/fi
Application granted granted Critical
Publication of FI114550B publication Critical patent/FI114550B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI934145A 1992-09-24 1993-09-22 Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi FI114550B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9220228 1992-09-24
GB929220228A GB9220228D0 (en) 1992-09-24 1992-09-24 Reshaped monoclonal antibodies against an immunologlobulin isotype
US95280292A 1992-09-25 1992-09-25
US95280292 1992-09-25

Publications (3)

Publication Number Publication Date
FI934145A0 FI934145A0 (fi) 1993-09-22
FI934145A FI934145A (fi) 1994-03-25
FI114550B true FI114550B (fi) 2004-11-15

Family

ID=26301683

Family Applications (2)

Application Number Title Priority Date Filing Date
FI934145A FI114550B (fi) 1992-09-24 1993-09-22 Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi
FI20040696A FI115838B (fi) 1992-09-24 2004-05-19 Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20040696A FI115838B (fi) 1992-09-24 2004-05-19 Ihmisen uusimuotoisten monoklonaalisen, IgE:lle spesifisen vasta-aineen käyttö IgE:n kvalitatiiviseen tai kvantitatiiviseen määrittämiseen

Country Status (18)

Country Link
EP (2) EP1452542A3 (he)
JP (2) JP3636737B2 (he)
KR (1) KR100298608B1 (he)
CN (2) CN1078250C (he)
AT (1) ATE264388T1 (he)
AU (1) AU675449B2 (he)
CA (1) CA2106719C (he)
CY (1) CY2583B2 (he)
DE (1) DE69333484T2 (he)
DK (1) DK0589840T3 (he)
ES (1) ES2219640T3 (he)
FI (2) FI114550B (he)
HK (1) HK1056182A1 (he)
IL (2) IL107049A (he)
MX (1) MX9305920A (he)
NO (1) NO318210B1 (he)
NZ (1) NZ248743A (he)
PT (1) PT589840E (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU7156996A (en) * 1995-09-13 1997-04-01 Genentech Inc. Methods for treatment of interstitial cystitis
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1056471A4 (en) * 1998-01-29 2001-05-30 Tanox Inc TREATMENT OF ATOPIC DERMATITIS USING IgE ANTAGONISTS
BRPI0316092B8 (pt) * 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
CN1829806A (zh) * 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法
AU2004315197B2 (en) * 2004-02-02 2009-06-04 Tanox, Inc. Identification of novel IgE epitopes
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407392B2 (en) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5104604A (en) * 1989-10-05 1992-04-14 Dexter Electronic Materials Div. Of Dexter Corp. Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトIgEに対するモノクローナル抗体
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.

Also Published As

Publication number Publication date
ATE264388T1 (de) 2004-04-15
FI934145A0 (fi) 1993-09-22
DE69333484D1 (de) 2004-05-19
EP0589840A1 (en) 1994-03-30
ES2219640T3 (es) 2004-12-01
IL107049A0 (en) 1993-12-28
EP1452542A2 (en) 2004-09-01
IL107049A (he) 2006-07-05
CN1088986A (zh) 1994-07-06
KR100298608B1 (ko) 2001-11-22
AU675449B2 (en) 1997-02-06
JPH06225788A (ja) 1994-08-16
JP3636737B2 (ja) 2005-04-06
CN1428352A (zh) 2003-07-09
CN1078250C (zh) 2002-01-23
FI115838B (fi) 2005-07-29
FI934145A (fi) 1994-03-25
CA2106719A1 (en) 1994-03-25
DE69333484T2 (de) 2005-03-24
IL173988A0 (en) 2006-07-05
MX9305920A (es) 1994-05-31
JP3718214B2 (ja) 2005-11-24
CA2106719C (en) 2006-03-28
NO318210B1 (no) 2005-02-21
KR940006602A (ko) 1994-04-25
EP1452542A3 (en) 2007-05-02
AU4748893A (en) 1994-03-31
CY2583B2 (en) 2009-11-04
FI20040696A (fi) 2004-05-19
NO933394D0 (no) 1993-09-23
EP0589840B1 (en) 2004-04-14
CN1254487C (zh) 2006-05-03
NO933394L (no) 1994-03-25
HK1056182A1 (en) 2004-02-06
NZ248743A (en) 1995-04-27
JP2004357712A (ja) 2004-12-24
PT589840E (pt) 2004-08-31
DK0589840T3 (da) 2004-07-26

Similar Documents

Publication Publication Date Title
US6072035A (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
EP0629240B1 (en) Altered antibodies, products and processes relating thereto
JP2912618B2 (ja) 組換えdna生産物及び製造法
Tempest et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo
AU763491B2 (en) Antibodies to CD23, derivatives thereof, and their therapeutic uses
JPH10509876A (ja) Cd38に対する擬人化抗体
JP2005538706A (ja) スーパーヒト化抗体
FI114550B (fi) Menetelmä immunoglobuliini-isotyyppiä vastaan suunnattujen uudelleenmuotoiltujen monoklonaalisten vasta-aineiden valmistamiseksi
JPH06509944A (ja) 特定Fcεレセプターのための免疫グロブリン変異体
JPH07504808A (ja) Cdrをグラフトしたヒト化キメラt細胞抗体
JPH05336989A (ja) 抗体誘導体
JP2002530108A (ja) ヒト化モノクローナル抗体
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
CN110114370B (zh) 能够与人白细胞介素-6受体结合的抗体或其抗原结合片段
JPH09510095A (ja) ヒトインターロイキン−4に対するヒト化モノクローナル抗体
JP2723671B2 (ja) GP▲II▼b/▲III▼aと反応性のヒト型化抗体
JP2001510329A (ja) ヒトモノクローナル抗体
RU2814471C2 (ru) Новые антитела против вируса гепатита b и их применение
JP2002515230A (ja) ベロ毒素iiを認識するヒト型化抗体、および該抗体を産生する細胞株
JP2011115175A (ja) スーパーヒト化抗体
JP2012152223A (ja) スーパーヒト化抗体

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 114550

Country of ref document: FI